Global Expansion MiStent SES is CE-marked and sold through a European distribution partner, STENTYS, indicating established international distribution channels and potential for entry into additional European markets or expansion through similar partnerships in other regions.

Strategic Acquisition Kossel Medical acquired Micell in 2021 and is actively promoting global strategy, suggesting ongoing corporate support for scaling operations and leveraging broader networks for market penetration and sales opportunities.

Technology Advantage Micell leverages supercritical fluid technology to address limitations of existing drug-eluting devices, presenting a unique value proposition to hospitals and cardiology centers seeking next‑gen solutions and differentiation in interventional cardiology.

Regulatory Footprint MiStent SES is not approved in the United States but is CE-marked and available in multiple countries, highlighting a potential near-term focus on international markets and need for US regulatory strategy and partnerships.

Growth Indicators Revenue is in the lower mid single digits with a small employee base, signaling a nimble organization with potential for rapid sales growth through channel partnerships, clinical endorsements, and expanded distribution deals in key markets.